

Network Wide Project Portfolio

For the quarter ending 31 March 2023



The **AHSN** Network



Network Wide Project Portfolio

Programme	Programme Details	RAG	ICS
<p>Blood pressure optimisation programme – Network Wide programme (Develop and deploy)</p>	<p>The AHSN blood pressure optimisation (BPO) programme supports local systems to ensure that people with hypertension are appropriately monitored and have their blood pressure and broader cardiovascular risk optimised to prevent heart attacks, strokes, and vascular dementia at scale. The objectives of the programme include:</p> <ul style="list-style-type: none"> 1) Supporting PCNs to implement the UCLP proactive care framework for hypertension (or analogous framework) to optimise clinical care and self-management in people with hypertension 2) Support PCNs to increase detection of people with hypertension through case-finding interventions 3) Support ICSs to reduce health inequalities by targeting the 20% most deprived populations and other local priority groups. <p>Q4 Update (Q4 Specific activity/delivery/milestones)</p> <ul style="list-style-type: none"> - Continued support at PCN level for hypertension case finding in BLMK. - Continued engagement with BLMK in developing a hypertension quality improvement programme. - Engagement with SE PHE/OHID teams to develop a community of practice for HTN for the South East. <p>In 2022/23 the AHSN supported ICBs with HTN improvements at system and practice level. We also made strong connections with regional NHSE and OHID colleagues and have worked with them to develop a community of practice to support ICBs going forward. Whilst the national programme comes to an end in its current form we look forward to continuing to support our ICBs with CVD prevention in general and a specific focus on HTN.</p>	<p>Green</p>	<p>BOB BLMK Frimley</p>
<p>CVD Prevention – Lipid Management and Familial Hypercholesterolaemia – Network Wide (Deploy)</p>	<p>The aim of the AHSN lipid management programme is to embed the NICE/AAC lipid management pathway into clinical practice and ensure that clinicians are aware and confident to prescribe the appropriate therapy to the appropriate patient cohort. The programme also aims to increase diagnosis rates for familial hypercholesterolaemia (FH).</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones)</p> <ul style="list-style-type: none"> - Project commencement for the Frimley System Transformation Fund project. Progress to date has included stakeholder engagement, identification of information needs, development of a logic model for evaluation and recruitment of staff to deliver the project. - Educational webinar delivered for BOB ICB on 26th January - Support provided to lipidology services with development of a referral proforma - Final draft of FH business case developed for BOB ICB - Successful collaborative lipid fund bid developed for BOB ICB <p>Continued membership of National lipids governance groups, and management of 3 x lipids public partners. Patient information videos on lipids adherence published on HeartUK website. Comms plan for dissemination of videos ongoing, and conversations with companies who manage doctors waiting room screen content taking place, with the view for videos to be displayed in waiting room screens.</p>	<p>Green</p>	<p>BOB BLMK Frimley</p>



Network Wide Project Portfolio

Programme	Programme Details	RAG	ICS
<p>Inclisiran - Network Wide (Deploy)</p>	<p>Inclisiran forms part of the Network Wide AHSN lipid management pathway but is reported separately as it is a separate commission. Inclisiran is a novel lipid management therapy that was introduced into the lipid management pathway in November 2021. The AHSN role is support the adoption of inclisiran through identifying barriers and addressing these.</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) Inclisiran activities are included in the lipid management description above. Of particular note for Inclisiran is: - BLMK Halycon project commenced - boosting the capacity of the community lipid service. - £170k secured for BOB ICB to support the adoption of the secondary care lipid management pathway.</p> <p>Whilst Inclisiran uptake across the Oxford AHSN region is comparatively low, there has been progress made in stakeholder engagement and in understanding barriers and developing solution. In 2023/24 we will continue to work to support the appropriate adoption of Inclisiran, as part of the AAC lipid management pathway.</p>	<p>Amber</p> <p>Rated as amber as orders significantly below the planned trajectory. This is in line with the national picture and is being addressed at a national level</p>	<p>BOB BLMK Frimley</p>
<p>Deteriorating Patient Safety Improvement Programme – Network Wide (Deploy)</p>	<p>During 21/22 we have concentrated on delivery of the phased adoption of deterioration management tools (primarily RESTORE2) and approaches across care homes to support the national ambition of these tools being used in 80% of non-acute settings by March 2024. For Q4 21/22 the region is reporting coverage in 53% of all care homes, with increases being seen in each preceding quarter. We expect there to be continued work in this area, and to continue to support our networks that are aligned to the future aims and ambitions.</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) RESTORE2 training has now been provided to 300 care home staff, primarily across Oxfordshire and Frimley. In addition we have trained 40 people though our train-the-trainer course which supports homes and support organisations to be self-sufficient in delivering this training in the future. Our main focus this quarter has been supporting the implementation of RESTORE2 in the remainder of Order of St John Care Trust homes not captured in the earlier pilot in previous quarters. We have also commenced training to a number of homes supported by (and in collaboration with) North Oxfordshire Rural Alliance (NORA) Primary Care Network.</p> <p>After providing an extended pilot period for RESTORE2 training, the PSC has collaborated with regional partners to revise and refine the content of delivery of training. This now provides a consistently well evaluated introduction to using RESTORE2. We are seeking external funding to maintain the training (ideally through the BOB ICB) so it is sustainable within the systems.</p>	<p>Amber</p> <p>Amber. Despite recent successes in training provision in Oxfordshire, adoption remains low at only with approx 20% of Care Homes using RESTORE2. This reflects the scale of numbers required to be trained to implement at scale. Training had also been 'gapped' in Frimley since a successful initial rollout. It was expected to recommence in Q4; however provision by Frimley Care Homes support service remains limited due to operational pressures. Oxford PSC virtual training continues to help to plug the training gap. RESTORE2 training remains limited in Berks W due to a seconded post. Although virtually delivered training is expected to accelerate roll-out in subsequent quarters, adoption is likely to remain below initial projection.</p>	<p>BOB Frimley</p>



Network Wide Project Portfolio

Programme	Programme Details	RAG	ICS
<p>First Episode Rapid Early Intervention for Eating Disorders (FREED) – Network Wide (Deploy)</p>	<p>FREED is an innovative, evidenced based, specialist care package for 16 to 25-year-olds with a first episode of an eating disorder of less than three years duration. FREED aims to overcome the barriers to early treatment and provides highly co-ordinated care, with a central focus on the reduction of an untreated disorder.</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) Consolidation of learning and a report on the successes of the programme has been developed regionally, including participation in a national shared learning event in London on Monday 27 March. Buckinghamshire’s FREED service assessed and engaged 11 patients who joined the FREED pathway in Q4.</p> <p>The national AHSN FREED programme closed on 31 March 2023. All Eating Disorder services in the Berkshire Healthcare and Oxford Health trusts have - or are in the process of - adopting FREED. The service is available to 16-25 year olds with a three-year (or less) undiagnosed eating disorder. The service is well-embedded within Berkshire and Buckinghamshire. Support will be offered to Oxfordshire’s service across the year ahead to ensure that knowledge and learning from the past couple of years is shared. The Community of Practice established across the South East will continue within existing structures and allow for good practice and inspiration to be shared. Successful webinars on the subjects of “The Art of the Possibility” innovations in Eating Disorders (90 participants), and on Peer Support within Eating Disorder services (69 participants) were well-received. Across the South East Region, almost 100 clinical staff were trained in FREED (20 from Oxfordshire, 13 from Berkshire, and 5 from Buckinghamshire).</p>	<p>Green</p>	<p>BOB Frimley</p>
<p>Focus ADHD – Introduction of computerised test into ADHD assessment – Network Wide (Deploy)</p>	<p>Focus ADHD aims to improve ADHD assessment for school age children. The core of the programme is implementation of a computerised test such as QbTest. This test was already in place in Berkshire and Oxfordshire CAMHS ADHD Services before the start of the programme in 2019. Buckinghamshire CAMHS has now implemented QbTest at two sites (Aylesbury and Wycombe) and Milton Keynes CAMHS has also implemented.</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) Combined total numbers of tests carried out in Q4 in the new sites (two Buckinghamshire CAMHS sites and Milton Keynes CAMHS) are below trajectory due to one of the areas having staff leave and then delays in being able to train new staff. Training is now scheduled for April and then numbers of QbTests undertaken will pick up again. For the year 2022/23 the tests undertaken at the new sites are 94% of the projected numbers due to this staff turnover issue.</p> <p>The national Focus ADHD programme came to an end in March 23. Buckinghamshire HealthCare Trust had decided at present not to implement QbTest, and all other sites in the Oxford AHSN area that diagnose ADHD in school age children now have QbTest available to support diagnosis.</p> <p>Oxford AHSN along with our colleagues in Kent, Surrey and Sussex and Wessex AHSNs, supported a Community of Practice over the course of the programme for those working in children’s ADHD assessment services with the SE Region. Two members of this Community of Practice have now agreed to run the Community of Practice in the future as AHSNs step back from this role, thus enabling sustainability of the best practice sharing element of the Focus ADHD programme in SE Region.</p>	<p>Green</p>	<p>BOB BLMK Frimley</p>
<p>Medicines Safety Improvement Programme – Network Wide (Develop and deploy)</p>	<p>Commission for 2022/3 is focused on reducing harm from opioids prescribed for non-cancer pain.</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) The partnership we have forged with with the Frimley ICB Pain Collaborative Board sees us well placed to progress the MedSIP objectives. We will develop a measurement plan in 2023/24 to monitor progress for this. Once measurement of the workplan is available, we will share this information with BOB MO leads.</p> <p>In addition, Frimley ICB has announced a MO initiative for 2023/4 which will remunerate GP practices to engage in QI work on opioid tapering, and undertake training in delivering Structured Medication Reviews; this will provide an important incentive into the system at a time when the QOF QI module on drugs of dependency is being withdrawn. We have agreed to provide support at system level for this scheme.</p> <p>We also plan to support the Frimley MO education programme to deliver a webinar for Primary Care on deprescribing opioids.</p>	<p>Green</p>	<p>Frimley</p>



Network Wide Project Portfolio

Programme	Programme Details	RAG	ICS
<p>MedTech Funding Mandate (MTFM) 2022/23 – Network Wide (Deploy)</p>	<p>The MFTM policy aims to accelerate the uptake of selected NICE approved medical devices, diagnostics and digital products, as identified by the Accelerated Access Collaborative. Existing products on the MTFM programme from 2021/22: SecurAcath, Placental Growth Factor (PIGF)-based testing, Heartflow and gammaCore. New products added for 2022/23: Urolift, GreenLight XPS, Rezum, PLASMA system (technologies to treat Benign Prostatic Hyperplasia (BPH), or enlarged prostate), Xpress (balloon sinus dilation), Spectra Optia (treatment for sickle cell disease) andThopaz + (digital chest drain)</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) Good progress with the MTFM programme during the year:</p> <ul style="list-style-type: none"> - Confirmation of current levels of adoption in the Thames Valley area, allowing targeted activity in areas of non-adoption - Confirmation of the “graduation” of PIGF-based testing, SecurAcath, GammaCore and Heartflow in 23/24 - Extensive discussion across Oxford, BLMK, Eastern and Wessex geographies with national and local commissioners and providers on red blood cell exchange provision for sickle cell patients, resulting in area-wide options appraisals being formulated to reconfigure both panned and out-of-hours service provision to address patient inequalities. - System-wide interest confirmed in Thopaz+ through the Thames Valley Respiratory Clinical Network, with some providers already taking steps to evaluate the product for adoption. - Pursuing the final few contacts to confirm possible value of XprESS adoption in the region 	<p>Green</p>	<p>BOB BLMK Frimley</p>
<p>Mental Health (MH) Patient Safety Improvement Programme – Network Wide (Deploy)</p>	<p>The emphasis of the MH SIP throughout Q4 was Reducing Restrictive Practice (RRP) and local engagement and discussion regarding improving sexual safety. Wards continued to experience the challenges of Q4; pressures on Trusts from Covid, staffing vacancies/use of bank staff and staff turnover. Covid pressures started to ease in March. The number of wards involved in RRP did not increase from Q4 to Q4 and remained at 6 including Q4 confirmation of a request from OH that we support a third ward.</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) Our three MH Trusts are engaged with the MH SIP. However Berkshire Healthcare which is working on RRP with two of its wards did not want support from the AHSN. This position changed very slightly in March. After a virtual meeting that repeated the offer of assistance and included an update on other ward projects supported by us Berkshire said they would try to send ward teams to our next live learning event (23 5 23).</p> <p>CNWL Milton Keynes Hazel ward are our most advanced project (adoption stage 6) despite changes in ward manager. Our work with Oxford Health is intensive. Supporting ward projects with in-person, on-site meeting requires quite a lot of capacity but achieves project progress. Supporting Buckinghamshire’s two wards has reduced to bi-weekly on-site meetings, the wards are making mixed progress (Ruby adoption stage 5, Sapphire still stage 4) due to some new issues around blanket restrictions on Sapphire ward. The appointment of new ward managers and matron in Q4 is really helping. We are also supporting 3 Forensic wards. Kestrel ward project is the most advanced and throughout Q4 we supported with weekly on-site meetings (now adoption stage 4). Watling worked on first change idea in Q4 (adoption stage 4), and we managed to get data to complete a first workbook. However Wenric ward is no longer pursuing a RRP project and instead has started an improving inpatient sexual safety project which we are supporting with bi-weekly meetings.</p> <p>The biggest change to activity in Q4 has been to begin working with Elysium at Thatcham. We are supporting one ward; Bucklebury, a medium secure male ward. We delivered a long half-day workshop in March, completed the driver diagram and potential areas for PDSA cycles are already identified. Currently quite confident a project can be delivered by programme end in September.</p> <p>Q4 saw the QI case study video of Oxford Health’s Kennet ward finalised and used at our (South of England 5 AHSN) live learning event on 21st of February. Along with other AHSNs we agreed to amalgamate further meetings of the national Forensic Wards network with PICU and Acute networks, to try to resolve low attendance.</p>	<p>Green</p>	<p>BOB BLMK Frimley</p>



Network Wide Project Portfolio

Programme	Programme Details	RAG	ICS
<p>Polypharmacy – Network Wide (Develop and deploy)</p>	<p>As of April 2022, Polypharmacy: Getting the Balance Right has been agreed as a network wide programme to be delivered by the AHSN Network. Oxford AHSN is in phase 1 of implementation. The core principle of the programme is to support local systems address problematic polypharmacy through establishing a community of practice; A community of practice; Population Health Management (Pillar 1); Education & Training (Pillar 2) and Public Behaviour Change (Pillar 3).</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) The polypharmacy programme will continue to be supported as an AHSN network programme rather than a national programme for an additional year (23/24) before being handed over to the participating Integrated Care Boards (ICB).</p> <p>Community of Practice (CoP) The second CoP for Frimley ICB was held on 08.02.23. This took place in the evening at the request of Local Pharmaceutical Committee Chairs to enable community pharmacists to join. 17 people attended. 61 people have expressed an interest in being part of the Frimley CoP. The first CoP is being organised for BLMK on 27.04.23. 71 people have expressed an interest in being part of the BLMK CoP.</p> <p>Action Learning Sets (ALS) A South-East AHSNS cohort is being planned and promoted for May and June. To date, 16 prescribers across Frimley, BOB and BLMK ICB have registered to attend. Additional cohorts are being planned to be delivered in 23/24.</p> <p>Patient behaviour change campaign 4 sites have come forward to take part in the pilot to test the Me and My Medicines Campaign. As of 04.04.23, 16 patients and 1 clinician have submitted feedback. These responses will contribute to a national level evaluation that will inform wider roll out. A local level focus group is being planned for 04.05.23 to gain additional insight from participating sites.</p> <p>Health inequalities dashboard Oxford AHSN have commissioned a polypharmacy health inequalities dashboard from Unity Insights. This was following a request from ICB Medicines Optimisation Leads for a greater focus on health inequalities to be included in the programme. The specification has been agreed and completion is planned for June 23.</p> <p>Communication Information about the programme and dates of planned events have been added to the Oxford AHSN website. This information is being via newsletters and the CoP.</p> <p>Alignment with ICB plans Polypharmacy has been included in medicines optimisation and medicines safety work plans for Frimley, BOB and BLMK ICB.</p>	<p>Green</p>	<p>BOB BLMK Frimley</p>
<p>Reducing inappropriate high dose opiate prescriptions for non-cancer pain - National (Develop)</p>	<p>The AHSN network has developed a whole systems approach to reducing harm from opioids to support local approaches to helping people live well with chronic non-cancer pain.</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) See Medicines Safety Improvement Programme above</p>	<p>Green</p>	<p>BOB BLMK Frimley</p>



Network Wide Project Portfolio

Programme	Programme Details	RAG	ICS
Transforming Wound Care - Network Wide (Develop and deploy)	<p>In 2022/23 we have started a programme of spread and adoption of the National Wound Care Strategy Programme as an evidence-based solution to improve Lower Limb Wound Care. We will be working with ICS and Trust stakeholders to develop effective delivery to reduce leg ulcer prevalence and reduction of cost in care. More precise aims will be worked up as the programme starts in Q1.</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) Successfully launched dedicated lower limb clinic within Frimley Health and Care ICS on the 4th April 2023. Feedback from the TES in Frimley Health and Care ICS has been very positive. The clinical nursing manager has reported that a key element of the pathway where clinicians are asked to implement compression immediately on presentation of wound has worked really well. Feedback from practice staff has been very positive and the programme has instilled a cultural focus on leg wound management. This has led to sparking other ideas of how to improve operational efficiency. The clinically pathway has led to more rapid diagnosis of lower limb issues and prompt referrals to the specialist services. They have a number of patient cases who have already benefited from the pathway with vast improvements to their overall lower limb health. We are hoping to publish some of these successes as case studies.</p>	Green	Frimley
Maternity and Neonatal Safety - Deterioration - Network Wide (Deploy)	<p>New National Maternity Early Warning Score tool designed to focus on early identification, escalation and response to deterioration in pregnant women. Currently Phase 1 of pilot testing.</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) Evaluation of pilot phases by NHSE and plans for implementation when NHSE are ready-Oxford are agreeable; Bucks unable to participate in implementation due to incompatibility across their trusts wide e-obs digital system.</p>	Green	BOB
Maternity and Neonatal Safety - Preterm Optimisation - Network Wide (Develop and Deploy)	<p>Optimisation of the preterm baby is a key priority outlined in Maternity and Neonatal Safety improvement Programme (MatNeoSIP) and in the BAPM Perinatal Management of Extreme Preterm Birth before 27 weeks.</p> <p>There are several elements within the optimisation care bundle which trusts are required to work together on, for example, place of birth, optimal cord management, normothermia, steroid and magnesium usage and early colostrum and breast milk which will ensure that the preterm baby has the best possible outcome.</p> <p>We are working collaboratively with a diverse group of stakeholders to improve outcomes for this preterm infants and experience for the families and staff who care for them.</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) Scoping discussions with Bucks New University re design and development of a simulation based multi professional education programme in response to the findings from the PTB stakeholder engagement exercises. Scoping costing to 'professionalise' the content of the antenatal counselling workshops with OxSTaR and an independent SIM company</p>	Green	BOB BLMK Frimley
Rapid Uptake Products - PCSK9i - National (Deploy)	<p>AAC RUP (forms part of the national lipid management programme)</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) This forms part of the national lipid management programme - commentary given above.</p>	Green	BOB BLMK Frimley



Network Wide Project Portfolio

Programme	Programme Details	RAG	ICS
Rapid Uptake Products - High Intensity Statins - National (Deploy)	<p>AAC RUP (forms part of the national lipid management programme)</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) This forms part of the national lipid management programme - commentary given above.</p>	Green	BOB, BLMK, Frimley
Rapid Uptake Products - Fractionally exhaled Nitrous Oxide (FeNO) - National (Deploy)	<p>AAC RUP - Fractional Exhaled Nitric Oxide (FeNO) project, for the diagnosis and management of asthma project has redesigned pathways across four PCNs, incorporating appropriate use of FeNO testing.</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) We procured an additional 7 Bedfont FeNO monitors for the BOB ICS. 6 of these will be used to help deliver the extended Integrated Severe Asthma Collaborative (ISAC) work, that is being funded through the Innovation for Healthcare Inequalities Programme (InHIP). We helped Healthier Oxford PCN write a case study that demonstrated an innovative solution utilising the EMIS clinical IT system to facilitate sharing of a single FeNO monitor across a PCN. We achieved the year end target for both FeNO devices and mouthpieces. The most recent data available from NHSE (February 2023) shows that Oxford AHSN currently tops the AHSN leader board for most FeNO devices placed into the system (69 from a target of 16).</p>	Green	BOB, BLMK, Frimley
Rapid Uptake Products - Asthma Biologics - National (Deploy)	<p>AAC RUP - Asthma Biologics programme, the programme is aiming to improve care for severe asthma patients through earlier identification of patients with uncontrolled asthma and treatment escalation to biologics for appropriate patients</p> <p>Q4 Update (Q4 Specific activity/delivery/milestones) Work on various comms activities to raise awareness about the impact of the Asthma Biologics Programme and support its closure. Decision to combine two respiratory programmes - FeNO and Asthma Biologics into one single asthma programme narrative, "Transforming Asthma Pathways". Release of case studies through AHSN Network to tell an impressive holistic story about the innovative and transformative work continuing across the asthma pathway. Continue to raise awareness about available resources for HCPs to improve uptake of e-learning modules. Many more HCPs completing two e-learning modules. Overall 96% of participants have provided positive feedback on modules All (9) PTF evaluation reports and clarification questions were reviewed and work continued on writing PTF Evaluation Summary report to show how PTF impacts the Asthma Biologics Programme. Three case studies drafted to show good examples of the delivered PTF projects. My AsthmaBiologic App, a homecare monitoring app - 2 pilot sites went live and 144 patients using the app. Successfully delivered:</p> <ul style="list-style-type: none"> Final joint FeNO/AB AHSN Leads meeting; great reflections received from Vicky Spellacy (AAC), Stuart Monk and clinical champions. AHSN leads provided very positive feedback and statements, such as "the programme shows power of the AHSNs!" Final AB PWG meeting; positive reflections received from National Respiratory Clinical Director (NHSE), NICE, Patient Reps, Clinical Champions, Stuart Monk and Industry partners. Joint presentation with Wessex AHSN the Asthma Biologics and FeNO national programmes at the AHSN Network Connecting the Network event <p>National: The AAC RUP Asthma Biologics Programme closed on 31st March 2023. The second year, 2022/23, of the two-year national programme delivery had proved to be successful. The programme was led, designed and delivered in collaboration (working with AAC, AHSN Network, Industry and the NHS System), creating significant impact across the asthma clinical pathway, from identification and diagnosis to monitoring and treatment.</p>	Green	BOB, BLMK, Frimley